MA-WASABI/ZERO-CIRCLE
10.7.2024 15:01:34 CEST | Business Wire | Press release
Zero Circle, a sustainable finance marketplace, and Wasabi Technologies, the hot cloud storage company, have partnered to develop a suite of sustainability-focused solutions for cloud storage that give businesses the data they need to make decisions that reduce their environmental impact.
Wasabi cloud storage integrated Zero Circle’s invoice-based carbon footprint calculator to give customers transparency and real-time assessment of their carbon footprint. Customers can upload their Wasabi invoice to Zero Circle’s carbon calculator to determine their estimated CO2 footprint based on actual data stored in a Wasabi storage region, increasing the accuracy of their ESG benchmarking with their peers and helping them make more sustainable business decisions.
According to the Wasabi 2024 Global Cloud Storage Index, sustainability ranks among the top three most important considerations for buyers when choosing a cloud storage service. Factors like ESG commitments, energy-efficient architecture design, and native tools for carbon footprint calculation are all increasingly important to modern enterprises as they adopt cloud infrastructure services. As a result, the survey found that cloud service providers must deliver accurate, reliable tools, metrics, and programs to meet customer expectations.
This joint initiative leverages Zero Circle's deep expertise in sustainability and product carbon footprint measurement with Wasabi's leadership in cloud storage to drive sustainability in the cloud storage industry and create innovative solutions that support businesses with their sustainability initiatives. The solution's unique features and flexibility make it a powerful resource for companies seeking to measure and track their cloud sustainability, such as real-time emissions calculations integrated directly into the purchases from supply chain partners.
“Partnering with Zero Circle underscores Wasabi’s dedication to providing top-tier, sustainable cloud storage solutions,” said David Boland, vice president of cloud strategy at Wasabi Technologies. “Zero Circle's carbon footprint calculation has already enabled Wasabi, our partners, and customers to gain a deeper understanding of our environmental impact. By integrating this solution into our supply chain, we are amplifying these benefits for everyone involved.”
"Announcing our collaboration with Wasabi marks a significant step in advancing environmental sustainability within the cloud storage sector,” said Hemanth Setty, founder and CEO of Zero Circle. “This partnership leverages our combined strengths and underscores our mutual dedication to fostering a more sustainable future, paving the way for innovative and groundbreaking solutions.”
The carbon footprint solution is now available to all Wasabi customers. The Zero Circle – Wasabi collaboration will also explore other eco-friendly initiatives, such as renewable energy procurement and carbon offset programs in an effort to further reduce environmental impact of cloud storage.
Additional Resources:
- For more information on Wasabi’s work with Zero Circle, visit wasabi.com/sustainability.
- To try Zero Circle’s invoiced-based carbon footprint calculator for Wasabi, visit https://cust.zerocircle.eco/wasabi.
- Join Wasabi, Zero Circle, and 451 Research July 16 at 1 p.m. ET/10 a.m. PT to learn how establishing sustainability goals for IT can help your business meet regulatory compliance more quickly. Read more details here.
About Zero Circle
Zero Circle is a green finance marketplace that simplifies access to green capital for mid-tier businesses. Its AI-powered platform streamlines sustainability assessments and reporting and automates financial and sustainability KPIs to incentivize green financing. The company helps its customers finance and build sustainable practices by tracking, managing, and reporting sustainability and financial performance with lenders, partners, and customers.
Click here to learn more about Zero Circle or follow them on LinkedIn and Twitter.
About Wasabi Technologies
Recognized as one of the technology industry’s fastest growing companies, Wasabi is on a mission to store the world's data by making cloud storage affordable, predictable and secure. With Wasabi, visionary companies gain the freedom to use their data whenever they like without being hit with unpredictable fees or vendor lock-in. Instead, they’re free to build best-of-breed solutions with the industry’s fastest-growing ecosystem of independent cloud application partners. Customers and partners all over the world trust Wasabi to help them put their data to work so they can unlock their full potential. Visit wasabi.com to learn more.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240710254246/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
WHOOP Expands Commitment to Women's Health by Including One-Year Subscription of Natural Cycles° App in Membership4.8.2026 11:00:00 CEST | Press release
The integration gives eligible WHOOP members seamless access to the only FDA-cleared hormone-free birth control app, with the first year of Natural Cycles° included for those new to the app as part of their WHOOP membership. WHOOP, the human performance company, today announced an expansion of its women’s health offering through an integration with Natural Cycles° (NC°), the only FDA-cleared, hormone-free birth control app. WHOOP is offering a 12-month subscription to the NC° app to eligible new Natural Cycles users. Members with compatible WHOOP devices can now automatically share overnight skin temperature with the NC° app to enable personalized fertility insights and hormone-free birth control. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260804399367/en/ WHOOP Expands Commitment to Women's Health by Including One-Year Subscription of Natural Cycles° App in Membership The Natural Cycles app, a Class II medical device, u
Alphatax Makes Two Acquisitions to Strengthen Transfer Pricing Capabilities4.8.2026 10:00:00 CEST | Press release
Acquisitions Expand Transfer Pricing Offering and Support Long-Term Platform Strategy Alphatax, the global tax compliance software provider, has today announced the acquisitions of TP Accurate and Intra Pricing Solutions, expanding its transfer pricing capabilities and reinforcing its ambition to build the world's first tax operating system. The acquisitions strengthen Alphatax's transfer pricing portfolio with complementary capabilities across financial transactions and documentation. TP Accurate provides specialist software for intra-group financing arrangements, while Intra Pricing Solutions' flagship product, TPGenie, enables multinational organisations and advisors to produce transfer pricing documentation using intelligent automation and AI. Together, they expand Alphatax's ability to support the full transfer pricing lifecycle, helping customers manage compliance more efficiently while improving governance and reducing audit risk. They also represent another step towards Alphata
LabPMM® Launches Global KMT2A MRD Testing Service to Support Menin Inhibitor Development and Acute Leukemia Care4.8.2026 09:10:00 CEST | Press release
LabPMM®, an Invivoscribe® subsidiary, today announced the global availability of its new KMT2A measurable residual disease (MRD) testing service. The highly sensitive digital PCR service is available to healthcare providers, clinical researchers, and biopharmaceutical partners through LabPMM’s global laboratory network, with CAP/CLIA-accredited testing available in the U.S. The service addresses a growing need for accurate molecular monitoring in acute leukemias.1,2,3 KMT2A rearrangements (KMT2Ar) are oncogenic drivers in acute myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL).4 These rearrangements are present in about 80% of infant cases and 5-15% of childhood and adult leukemia cases.5 KMT2Ar leukemias are associated with chemotherapy resistance, high relapse rates, and poor clinical outcomes.5 The emergence of menin inhibitors is transforming the therapeutic landscape for patients with AML and ALL, particularly those with KMT2A-rearranged and NPM1-mutated disease.6 The
“HATSUNE MIKU LIGHTS TOKYO” Debuts on July 254.8.2026 09:00:00 CEST | Press release
Giant Hatsune Miku Returns to Light Up Tokyo’s Night! The Tokyo Metropolitan Government has been presenting year-round projection mapping displays on the Tokyo Metropolitan Government Building, using light and sound to showcase a wide range of artistic expressions as part of its efforts to create new nighttime tourism attractions in Tokyo. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260802298570/en/ © Crypton Future Media, INC. On Saturday, July 25, "HATSUNE MIKU LIGHTS TOKYO", featuring the globally beloved virtual singer Hatsune Miku, held its first screening. The work brings the world of the popular song “M@GICAL☆CURE! LOVE ♥ SHOT!” to life across the entire façade of the Tokyo Metropolitan Government Building. Since its launch in February 2024, “TOKYO Night & Light” has welcomed visitors from Japan and around the world, with total attendance surpassing 1.55 million. As one of Tokyo’s emerging landmark attractions, the
Mosaic Therapeutics appoints Dr Allison Jeynes as Chair of the Board4.8.2026 09:00:00 CEST | Press release
Accomplished life sciences leader with a proven track record of driving successful development of novel therapeutics, joins Mosaic to guide its next phase of growthAllison brings three decades of drug development, board and executive leadership experience to support Mosaic’s transition towards a clinical-stage company Mosaic Therapeutics, Ltd, (‘Mosaic’, or ‘the Company’) an oncology therapeutics company developing novel, targeted drug combinations across a range of haematological and solid cancers, today announced the appointment of Dr Allison Jeynes as Chair of the Board to support its next phase of growth and advancement towards clinical development. Allison succeeds Dr Edward Hodgkin, who remains a Non-Executive Director of the Board. Allison is a UK-trained oncologist and highly-experienced life sciences leader, and brings over three decades of drug development and executive experience to Mosaic Therapeutics. As CEO of Avillion, a clinical development company, for the last 13 year
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom